MB, Levis & Associates
YARW

MB, Levis & Associates’s Yarrow Bioscience YARW Stock Holding History

MB, Levis & Associates’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$450 Sell
20
-1
-5% -$34 ﹤0.01% 241
2026
Q2 		$677 Hold
21
– – ﹤0.01% 245
2026
Q1 		$622 Hold
21
– – ﹤0.01% 224
2025
Q4 		$604 Hold
21
– – ﹤0.01% 236
2025
Q3 		$349 Hold
21
– – ﹤0.01% 239
2025
Q2 		$1.72K Hold
21
– – ﹤0.01% 246
2025
Q1 		$1.64K Hold
21
– – ﹤0.01% 253
2024
Q4 		$3.49K Hold
21
– – ﹤0.01% 234
2024
Q3 		$1.96K Hold
21
– – ﹤0.01% 259
2024
Q2 		$2.05K Hold
21
– – ﹤0.01% 257
2024
Q1 		$3.2K Hold
21
– – ﹤0.01% 238
2023
Q4 		$2.43K Hold
21
– – ﹤0.01% 243
2023
Q3 		$4.21K Hold
21
– – ﹤0.01% 225
2023
Q2 		$4.27K Hold
21
– – ﹤0.01% 223
2023
Q1 		$3.21K Hold
21
– – ﹤0.01% 236
2022
Q4 		$2.81K Buy
+21
New +$4.2K ﹤0.01% 224

Other funds holding YARW

US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Hurley Capital
Hurley Capital New York $206M AUM 18.12% 1-Year Est. Return

MB, Levis & Associates's YARW Position: Q3 2026 in Review

MB, Levis & Associates reduced its Yarrow Bioscience (YARW) stake by 4.8% in Q3 2026, selling an estimated $34 and leaving 20 shares worth $450. The position accounts for ﹤0.01% of the portfolio, ranked #241.

MB, Levis & Associates first reported a position in YARW in Q4 2022 and has held it in 16 quarters since. The position peaked at $4.27K in Q2 2023. 6 funds tracked by Wall St. Rank hold YARW as of Q3 2026.

  • MB, Levis & Associates held 20 shares of Yarrow Bioscience worth $450 as of Q3 2026.
  • MB, Levis & Associates sold 1 Yarrow Bioscience share in Q3 2026, an estimated $34.
  • Yarrow Bioscience made up ﹤0.01% of MB, Levis & Associates's portfolio in Q3 2026, its #241 holding.
  • MB, Levis & Associates first reported a position in Yarrow Bioscience in Q4 2022 and has held it in 16 quarters since.
  • MB, Levis & Associates's Yarrow Bioscience position peaked at $4.27K in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2026.

Based on MB, Levis & Associates's 13F filing for Q3 2026, filed 16 Oct 2026.